Halozyme Therapeutics, Inc. (HALO)
62.88
-0.45
(-0.71%)
USD |
NASDAQ |
Dec 08, 16:00
62.05
-0.83
(-1.32%)
After-Hours: 20:00
Halozyme Therapeutics Cash from Operations (TTM): 611.00M for Sept. 30, 2025
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Merck & Co., Inc. | 17.06B |
| ANI Pharmaceuticals, Inc. | 170.72M |
| Bristol Myers Squibb Co. | 16.62B |
| Twist Bioscience Corp. | -47.63M |
| Aurinia Pharmaceuticals, Inc. | 120.62M |